Neuromuscular junction denervation and terminal Schwann cell loss in the hTDP‐43 overexpression mouse model of amyotrophic lateral sclerosis

Aims Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with complex aetiology. Despite evidence of neuromuscular junction (NMJ) denervation and ‘dying‐back’ pathology in models of SOD1‐dependent ALS, evidence in other genetic forms of ALS is limited by a lack of suitable animal models. TDP‐43, a key mediator protein in ALS, is overexpressed in neurons in Thy1‐hTDP‐43WT mice. We therefore aimed to comprehensively analyse NMJ pathology in this model of ALS. Methods Expression of TDP‐43 was assessed via western blotting. Immunohistochemistry techniques, alongside NMJ‐morph quantification, were used to analyse motor neuron number, NMJ denervation status and terminal Schwann cell morphology. Results We present a time course of progressive, region‐specific motor neuron pathology in Thy1‐hTDP‐43WT mice. Thy1‐driven hTDP‐43 expression increased steadily, correlating with developing hindlimb motor weakness and associated motor neuron loss in the spinal cord with a median survival of 21 days. Pronounced NMJ denervation was observed in hindlimb muscles, mild denervation in cranial muscles but no evidence of denervation in either forelimb or trunk muscles. NMJ pathology was restricted to motor nerve terminals, with denervation following the same time course as motor neuron loss. Terminal Schwann cells were lost from NMJs in hindlimb muscles, directly correlating with denervation status. Conclusions Thy1‐hTDP‐43WT mice represent a severe model of ALS, with NMJ pathology/denervation of distal muscles and motor neuron loss, as observed in ALS patients. This model therefore provides an ideal platform to investigate mechanisms of dying‐back pathology, as well as NMJ‐targeting disease‐modifying therapies in ALS. Thy1‐hTDP‐43WT mice represent a severe model of ALS, with NMJ pathology/denervation of distal muscles and motor neuron loss, as observed in ALS patients. Here, we characterise robust NMJ denervation in hindlimb muscles that correlates with the loss of terminal Schwann cells. This model, therefore, provides an ideal platform to investigate the mechanisms of dying‐back pathology, as well as NMJ‐targeting disease‐modifying therapies in ALS.